{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:35:50Z","timestamp":1790145350728,"version":"4.0.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years. Because interferon-\u03b1 promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would be a useful therapy for Erdheim-Chester disease. We therefore treated 3 patients with advanced disease with interferon-\u03b1 at a starting dose of 3 to 6 \u00d7 106 units, which was later reduced, during maintenance, to 1 \u00d7 106 units subcutaneous 3 times per week. Marked improvement was noted in all patients, with substantial retro-orbital disease regression within 1 month. Improvement in bone lesions, pain, diabetes insipidus, and other manifestations was gradual over many months. Responses were durable (3+ to 4.5+ years). Our observations suggest that this well-tolerated therapy has a significant effect on the course and outcome of Erdheim-Chester disease.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2238","type":"journal-article","created":{"date-parts":[[2005,7,15]],"date-time":"2005-07-15T00:24:22Z","timestamp":1121387062000},"page":"2992-2994","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":171,"title":["Successful treatment of Erdheim-Chester disease, a non\u2013Langerhans-cell histiocytosis, with interferon-\u03b1"],"prefix":"10.1182","volume":"106","author":[{"given":"Fadi","family":"Braiteh","sequence":"first","affiliation":[{"name":"From the Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; the Section of Ophthalmology, Department of Plastic Surgery, M.D. Anderson Cancer Center, Houston, TX; and the Jules Stein Eye Institute, University of California, Los Angeles (UCLA) Santa Monica, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Boxrud","sequence":"additional","affiliation":[{"name":"From the Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; the Section of Ophthalmology, Department of Plastic Surgery, M.D. Anderson Cancer Center, Houston, TX; and the Jules Stein Eye Institute, University of California, Los Angeles (UCLA) Santa Monica, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Esmaeli","sequence":"additional","affiliation":[{"name":"From the Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; the Section of Ophthalmology, Department of Plastic Surgery, M.D. Anderson Cancer Center, Houston, TX; and the Jules Stein Eye Institute, University of California, Los Angeles (UCLA) Santa Monica, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"From the Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; the Section of Ophthalmology, Department of Plastic Surgery, M.D. Anderson Cancer Center, Houston, TX; and the Jules Stein Eye Institute, University of California, Los Angeles (UCLA) Santa Monica, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218493488800_REF1","doi-asserted-by":"crossref","unstructured":"Chester W. U\u0308ber lipoidgranulomatose (Over lipoid granulomatosis). Virchows Arch Pathol Anat Physiol. 1930;279: 561-602.","DOI":"10.1007\/BF01942684"},{"key":"2020021218493488800_REF2","doi-asserted-by":"crossref","unstructured":"Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75: 157-169.","DOI":"10.1097\/00005792-199605000-00005"},{"key":"2020021218493488800_REF3","doi-asserted-by":"crossref","unstructured":"Babu RP, Lansen TA, Chadburn A, Kasoff SS. Erdheim-Chester disease of the central nervous system. Report of two cases. J Neurosurg. 1997;86: 888-892.","DOI":"10.3171\/jns.1997.86.5.0888"},{"key":"2020021218493488800_REF4","doi-asserted-by":"crossref","unstructured":"Ivan D, Neto A, Lemos L, Gupta A. ErdheimChester disease: a unique presentation with liver involvement and vertebral osteolytic lesions. Arch Pathol Lab Med. 2003;127: 337-339.","DOI":"10.5858\/2003-127-e337-EDAUPW"},{"key":"2020021218493488800_REF5","doi-asserted-by":"crossref","unstructured":"Wimpissinger TF, Schernthaner G, Feichtinger H, Stackl W. Compression of kidneys in ErdheimChester disease of retroperitoneum: Open surgical approach. Urology. 2005;65: 798.","DOI":"10.1016\/j.urology.2004.10.051"},{"key":"2020021218493488800_REF6","doi-asserted-by":"crossref","unstructured":"Bisceglia M, Cammisa M, Suster S, Colby TV. Erdheim-Chester disease: clinical and pathologic spectrum of four cases from the Arkadi M. Rywlin slide seminars. Adv Anat Pathol. 2003;10: 160-171.","DOI":"10.1097\/00125480-200305000-00004"},{"key":"2020021218493488800_REF7","doi-asserted-by":"crossref","unstructured":"Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28: 9-14.","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P"},{"key":"2020021218493488800_REF8","doi-asserted-by":"crossref","unstructured":"Reid CD, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol. 1992;149: 2681-2688.","DOI":"10.4049\/jimmunol.149.8.2681"},{"key":"2020021218493488800_REF9","doi-asserted-by":"crossref","unstructured":"Luft T, Luetjens P, Hochrein H, et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol. 2002;14: 367-380.","DOI":"10.1093\/intimm\/14.4.367"},{"key":"2020021218493488800_REF10","doi-asserted-by":"crossref","unstructured":"Luft T, Pang KC, Thomas E. Type I interferons enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161: 1947-1953.","DOI":"10.4049\/jimmunol.161.4.1947"},{"key":"2020021218493488800_REF11","doi-asserted-by":"crossref","unstructured":"Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001;132: 945-947.","DOI":"10.1016\/S0002-9394(01)01141-2"},{"key":"2020021218493488800_REF12","doi-asserted-by":"crossref","unstructured":"Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999;85: 2278-2290.","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U"},{"key":"2020021218493488800_REF13","doi-asserted-by":"crossref","unstructured":"Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135: 844-845.","DOI":"10.7326\/0003-4819-135-9-200111060-00027"},{"key":"2020021218493488800_REF14","doi-asserted-by":"crossref","unstructured":"Jendro MC, Zeidler H, Rosenthal H, Haller H, Schwarz A. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol.2004;23: 52-56.","DOI":"10.1007\/s10067-003-0801-7"},{"key":"2020021218493488800_REF15","unstructured":"Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6\/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol. 2003;21: 232-236."},{"key":"2020021218493488800_REF16","doi-asserted-by":"crossref","unstructured":"Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88: 844-847.","DOI":"10.1136\/bjo.2003.035584"},{"key":"2020021218493488800_REF17","doi-asserted-by":"crossref","unstructured":"Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye. 2000;14: 606-612.","DOI":"10.1038\/eye.2000.151"},{"key":"2020021218493488800_REF18","doi-asserted-by":"crossref","unstructured":"Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85: 1220-1224.","DOI":"10.1136\/bjo.85.10.1220"},{"key":"2020021218493488800_","doi-asserted-by":"crossref","unstructured":"Shields JA, Karcioglu ZA, Shields CL, Eagle RC, Wong S. Orbital and eyelid involvement with Erdheim-Chester disease. A report of two cases. Arch Ophthalmol. 1991;109: 850-854.","DOI":"10.1001\/archopht.1991.01080060114037"},{"key":"2020021218493488800_REF20","unstructured":"Johnson MD, Aulino JP, Jagasia M, Mawn LA. Erdheim-Chester disease mimicking multiple meningiomas syndrome. AJNR Am J Neuroradiol. 2004;25: 134-137."},{"key":"2020021218493488800_REF21","doi-asserted-by":"crossref","unstructured":"Brown RE. Interferon-alpha therapy, protein kinase C-alpha and Langerhans cell histiocytosis. Med Pediatr Oncol. 2003;41: 63-64.","DOI":"10.1002\/mpo.10297"},{"key":"2020021218493488800_REF22","doi-asserted-by":"crossref","unstructured":"Chang SE, Koh GJ, Choi JH, et al. Widespread skin-limited adult Langerhans cell histiocytosis: long-term follow-up with good response to interferon alpha. Clin Exp Dermatol. 2002;27: 35-37.","DOI":"10.1046\/j.1365-2230.2002.00989.x"},{"key":"2020021218493488800_REF23","doi-asserted-by":"crossref","unstructured":"Palomera L, Domingo JM, Olave T, Romero S, Gutierrez M. Sinus histiocytosis with massive lymphadenopathy: complete response to lowdose interferon-alpha [letter]. J Clin Oncol. 1997;15: 2176.","DOI":"10.1200\/JCO.1997.15.5.2176"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/2992\/1635831\/zh802105002992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/9\/2992\/1635831\/zh802105002992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T19:16:27Z","timestamp":1683141387000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/9\/2992\/21903\/Successful-treatment-of-ErdheimChester-disease-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2238","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}